(CercleFinance.com) – Eli Lilly shared updated data from a clinical trial of olomorasib (a KRAS G12C protein inhibitor) as monotherapy in patients with advanced solid tumors, as well as olomorasib when It is combined with Keytruda (from Merck) in patients with advanced non-small cell lung cancer (NSCLC).
The results showed ‘encouraging’ efficacy and tolerability, opening ‘promising’ prospects for the use of olomorasib, particularly in NSCLC where new treatment options are needed, the laboratory emphasizes.
Scientists say they are excited about the possibilities of combining olomorasib with pembrolizumab-containing regimens for first-line treatments of NSCLC.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
